MedTrace Logo

S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00003587 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2012-10-08

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Randomized phase II trial to study the effectiveness of two different combination chemotherapy regimens in treating patients who have stage IIIB or stage IV non-small cell lung cancer

Conditions

Interventions

DRUG

carboplatin

AUC=5.5 day 1 every 21 days X 3

DRUG

cisplatin

IV cisplatin 100 mg/m\^2 day 1 every 21 days X 3

DRUG

docetaxel

IV docetaxel 75 mg/m\^2 day 1 every 21 days X 3

DRUG

gemcitabine

IV gemcitabine 1,000 mg/m\^2/day, days 1 and 8 every 21 days X3

DRUG

paclitaxel

IV paclitaxel 225 mg/m\^2/day, day 1 every 21 days X 3

DRUG

vinorelbine

IV vinorelbine 25 mg/m\^2/day, days 1 and 8 every 21 days X 3

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Martin J. Edelman, MD · Veterans Affairs Medical Center - Baltimore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-10-31
Primary Completion
2001-01-31
Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003587 on ClinicalTrials.gov